Michelle I Olufeso
- Founder and CEO of MIO Consult GmbH, an accounting consultancy specialising in International Financial Reporting Standards (IFRS) accounting for licence deals in the pharma-biotech-medtech world.
- Formerly with Roche (2004-2016) as Head of Accounting and External Relations, Michelle managed the accounting for all R&D alliances within the Roche Group globally.
- Highly respected for her contribution to IFRS standard setting and EU adoption of the standards.
- The types of financial statements and their components relevant for deal accounting.
- To understand the accounting terminology and implications of licensing contracts.
- How the classification of the IP transferred in a deal impacts on deal accounting.
- How to mitigate the risk of having income fluctuations in financial statements as a result of uncertainty around R&D deals.
- How to determine the accounting implications of in-licensing deals before deal signing.
- How to determine the accounting implications of out-licensing deals before deal signing.
- The accounting implications of equity transfers before deal signing.
- You will be able to use decision trees that show in advance how any licensing deal will be accounted for.
- You will have the opportunity to ask questions to a finance expert about the deals you are working on.
Why You Should Attend
The Content: Most BusDev & Licensing executives in pharma, biotech or medtech companies have little understanding of accounting implications of the deals they are working on. As a result, when the deals are signed, the accounting treatment is often contrary to what was expected by the executives. By attending this course, you will be well equipped to pre-determine the accounting treatment to ensure there are no surprises post-deal signing.
The Expert: As Roche’s former Head of Accounting, managing the accounting for all R&D alliances within the Roche Group globally, Michelle experienced firsthand the implications of a lack of understanding of accounting principles across functions involved in deal making. Her passion for inspiring others towards excellence led her to head the Roche Diploma in Accounting (RDA) trainings (Basic and Advanced), to develop training materials and to actively facilitate workshops worldwide. Her roles have enhanced her ability to have in-depth discussions with various stakeholders and high-profile professionals, from different countries, having very different backgrounds, across very different accounting and non-accounting topics.
The Accounting Implications of Pharma Licensing Deals for BD&L Managers course is the only available public training course delivered by Michelle I Olufeso on this topic.
Agenda of Accounting Implications of Pharma Licensing Deals for BD&L Managers
Important: all hours are noted in CET/Brussels Time, so carefully convert into your local time zone!
Short breaks will be offered throughout the day.
Welcome & Audience Expectations (~30 min)
Financial Statements: Accounting Considerations for License Deals (~30 min)
Elements of Licensing Deals With Accounting Implications (~1 h)
Accounting for In-Licensing Deals (~1 h 30 min)
Transfer of Equity: Accounting Considerations and Implications (~45 min)
Accounting for Out-Licensing Deals (~1 h 45 min)
Summary & Final Q&A (~30 min)
>> Click here if you wish to receive the PDF brochure of this course
Michelle uses real-life cases to illustrate the theory. Interactive sessions, including a decision tree exercise, are embedded in this programme to ensure you leave equipped with actionable knowledge.
One of the most valuable aspects of attending any CELforPharma course is not only being able to have your specific questions answered by a leading expert, but also having the opportunity to share experiences and have in-depth discussions with your international peers.
|The typical audience size of our courses ranges from 6 to 20 (max) participants.|
Who Should Attend?
- Business Development Executives who scout and negotiate deals.
- Legal Executives who draft term sheets and the actual contracts.
- Finance Executives who need to understand deal structures, legal terminology and the accounting implications.
- Pharma, Biotech and Medtech Partnering Executives who source deals to complement existing portfolio.
- R&D or Disease Biology Area (DBA) Executives who want to better inform their finance colleagues about the nature of the science behind the IP transferred in deals.
- Executives in Marketing and Distribution who want to better inform their finance colleagues about the marketing elements to be transferred in deals.
As this course is delivered by Michelle I Olufeso from MIO Consult GmbH, a leading pharma consultancy company, executives from other professional service agencies should request approval prior to registering for this course. Please contact Annelies Swaan, Director Business Operations, for more information (firstname.lastname@example.org, tel +32 (0)2 709 01 42).
Below is a non-exhaustive list of past participants who have benefited from attending this course.
|Global Head Business Development and Licensing Animal Health||Boehringer Ingelheim||Germany|
|Respiratory & Neonatology Biotech Specialist||Chiesi||Italy|
|Senior Manager Business Development||EUSA Pharma||United Kingdom|
|Head of Finance, Tax, Accounting||Sotio||Czech Republic|
Dates & Locations
Currently this CELforPharma course is planned to only be held live online (hosted in Zoom).
18 November 2021, live online
18 May 2022, live online
30 November 2022, live online
Included in the Registration Fee
- Access to a small-class (max 20 participants), expert led course in real-time, using an interactive platform for break-out rooms, whiteboard exercises, polling, plenary discussions and chats.
- Course material, which will be provided to you in both digital format (by email) and in hard copy (by post, so you can make notes during the course).
- Certificate of attendance signed by the expert and CELforPharma.
Special Offer for Biotech Executives
Executives from biotech start-ups (companies that do not have products on the market yet) and academia can attend this course for € 1 070 (excl. VAT). Please contact Annelies Swaan, Director, Business Operations, (email@example.com) for more details.
Team discounts can be offered to 3 or more delegates from the same company.
Contact Annelies Swaan, Director Business Operations, (firstname.lastname@example.org) for more details.
How to Register
- Click the "Register Here" button on this page.
- Choose a course date, then fill out your personal details and company / invoicing details.
- Choose to pay via bank transfer or by credit card.
- Click "Confirm Registration". You will be sent an automatic email confirming your registration followed by a personal email containing an invoice and further payment instructions.
For assistance in registering, raising a PO or invoicing, please do not hesitate to contact Kealeigh Steel.
(email: email@example.com or call: +32 2 709 01 45)
Transfer & Cancellation Policy
- If a registrant cannot attend the scheduled course, he/she can avoid any cancellation charge by sending a suitable replacement participant.
- Alternatively, the registrant can transfer once at no extra cost, until 3 weeks prior to the event, to another course held within one year of the original course date.
- Up to 6 weeks prior to the course: cancellation fee of € 400 per participant.
- Up to 5 weeks prior to the course: 25% of the invoiced registration fee.
- Up to 4 weeks prior to the course: 50% of the invoiced registration fee.
- Up to 3 weeks prior to the course: 75% of the invoiced registration fee.
- Fewer than 3 weeks or if no notification received: registrant liable to pay invoiced registration fee.
- If a registrant postpones his/her participation to a future course, and cancels again, no refund can be claimed for registration fees.